文献速递白血病

急性髓系白血病骨髓核心活检转录组学揭示治疗反应特异性的骨-间充质特征

Transcriptomics of acute myeloid leukaemia core bone marrow biopsies reveals distinct therapy response-specific osteo-mesenchymal profiles.
PubMed 文献 · Br J Haematol · 2022-11-10

研究对急性髓系白血病患者诊断时及以蒽环类和阿糖胞苷为基础的诱导化疗2周后的配对骨髓核心活检进行RNA-seq和组织学分析,比较缓解者(治疗后原始细胞<5%)与未缓解者(治疗后原始细胞≥5%)。缓解者中波形蛋白(VIM)、血小板衍生生长因子受体β(PDGFRB)和Snail家族转录抑制因子2(SNAI2)转录本富集,未缓解者中双糖链蛋白聚糖(BGN)、骨桥蛋白(SPP1)和骨连接蛋白(SPARC)等成骨细胞成熟相关转录本富集。

要点

  • 缓解者骨髓核心活检中VIM、PDGFRB和SNAI2转录本富集,提示间充质群体再激活。
  • 未缓解者中BGN、SPP1和SPARC等成骨细胞成熟相关转录本富集。
  • 首次在骨髓核心活检中直接展示与AML诱导化疗反应相关的不同成骨和间充质转录组特征。

核心结论

  • 在骨髓核心活检中直接评估发现,急性髓系白血病诱导化疗反应与不同的骨-间充质转录组特征相关。

研究设计与样本

  • 研究比较了诊断时和以蒽环类和阿糖胞苷为基础的诱导化疗2周后配对的人骨髓核心活检,采用RNA-seq和组织学分析。
  • 缓解者定义为治疗后原始细胞<5%,未缓解者定义为治疗后原始细胞≥5%。

主要发现

  • 缓解者中波形蛋白(VIM)、血小板衍生生长因子受体β(PDGFRB)和Snail家族转录抑制因子2(SNAI2)转录本富集。
  • 未缓解者中双糖链蛋白聚糖(BGN)、骨桥蛋白(SPP1)和骨连接蛋白(SPARC)等成骨细胞成熟相关转录本富集。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

While the bone marrow (BM) microenvironment is significantly remodelled in acute myeloid leukaemia (AML), molecular insight into AML-specific alterations in the microenvironment has been historically limited by the analysis of liquid marrow aspirates rather than core biopsies that contain solid-phase BM stroma. We assessed the effect of anthracycline- and cytarabine-based induction chemotherapy on both haematopoietic and non-haematopoietic cells directly in core BM biopsies using RNA-seq and histological analysis. We compared matched human core BM biopsies at diagnosis and 2 weeks after cytarabine- and anthracycline-based induction therapy in responders (<5% blasts present after treatment) and non-responders (≥5% blasts present after treatment). Our data indicated enrichment in vimentin (VIM), platelet-derived growth factor receptor beta (PDGFRB) and Snail family transcriptional repressor 2 (SNAI2) transcripts in responders, consistent with the reactivation of the mesenchymal population in the BM stroma. Enrichment of osteoblast maturation-related transcripts of biglycan (BGN), osteopontin (SPP1) and osteonectin (SPARC) was observed in non-responders. To the best of our knowledge, this is the first report demonstrating distinct osteogenic and mesenchymal transcriptome profiles specific to AML response to induction chemotherapy assessed directly in core BM biopsies. Detailing treatment response-specific alterations in the BM stroma may inform optimised therapeutic strategies for AML.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Treaba DO, Bonal DM, Chorzalska A, et al. Transcriptomics of acute myeloid leukaemia core bone marrow biopsies reveals distinct therapy response-specific osteo-mesenchymal profiles. Br J Haematol. 2022. PMID: 36354085. doi:10.1111/bjh.18513

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。